Secretin vs Lixisenatide

Head-to-head comparison of Secretin (Human Secretin) and Lixisenatide (Exendin-4-derived GLP-1 receptor agonist) — benefits, dosing, side effects, research data, and where to buy.

Research Score

PropertySecretinLixisenatide
CategoryGastrointestinalWeight Management
Full NameHuman SecretinExendin-4-derived GLP-1 receptor agonist
Molecular Weight3055.4 Da4858 Da
Half-Life5-7 minutes2-4 hours
Amino Acids2744
Typical Dose0.2 mcg/kg IV10-20 mcg daily
RouteIntravenousSubcutaneous
Purity≥98%≥98%
Studies Count800400
Research StatusClinicalApproved

Secretin Benefits

  • stimulates-pancreatic-secretion
  • supports-bicarbonate-release
  • aids-duodenal-pH-control
  • helps-digestive-coordination

Lixisenatide Benefits

  • postprandial glucose control
  • modest weight loss
  • appetite reduction
  • short-acting option

Secretin Dosing

0.2 mcg/kg IV diagnostic dose|research infusion protocols|short bolus administration

Lixisenatide Dosing

10 mcg SC daily for 14 days|Increase to 20 mcg daily|Inject before the first meal of the day

Secretin Side Effects

  • flushing
  • nausea
  • abdominal-cramping

Lixisenatide Side Effects

  • nausea
  • vomiting
  • hypoglycemia when combined with insulin

Research Overview

Secretin

Secretin is a classic GI hormone with extensive physiology literature and established diagnostic use. It remains important for studying pancreatic secretory function, biliary responses, and duodenal feedback.

Lixisenatide

Lixisenatide produces small but measurable weight loss in diabetes trials while improving postprandial glucose excursions. Its shorter half-life makes it a useful reference compound for first-generation incretin mimetics.

Ready to buy?

Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.

Common Stacking Partners

Secretin stacks with:

pancreatic-enzymesacid-controlmeal-timing

Lixisenatide stacks with:

basal-insulinmeal-plan
pancreatic-secretionbicarbonateduodenal-hormonedigestionGLP-1RAshort-actingpostprandial-controlweight-loss-adjacent